3상모집 중단 (진행 중)
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
연구 개요
This study will look at how much cagrilintide helps people with overweight or obesity and type 2 diabetes lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participant will either get cagrilintide or placebo. Which treatment participant get is decided by chance. Participants are two times more likely to get cagrilintide than placebo. Like all medicines, the study medicine may have side effects. For each participant, the study will last for about 1 year and 6 months.
- 스폰서
- 리드: 노보노디스크
- 적응증
- Overweight, Obesity, Type 2 Diabetes
- 중재
- Cagrilintide, Placebo (matched to Cagrilintide)
- 목표 등록
- 330명
- 시작일
- 2025-11-05
- 완료(예정)
- 2027-06-30
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.